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Novel anticoagulants in clinical development: focus on factor Xa
and direct thrombin inhibitors
Abstract
Vitamin K antagonists are the mainstay in the prevention and treatment of thromboembolic diseases.
Although effective under optimal conditions, several drawbacks are imminent to the long-term
application of these drugs due to their narrow therapeutic window, interactions with other drugs as well
as the need for regular monitoring and the risk of a recurrent event versus the risk of bleeding. To
overcome these downsides, novel anticoagulants are being developed; in contrast to vitamin K
antagonists, these novel agents specifically and selectively block central elements of the coagulation
cascade. Several clinical trials have demonstrated the efficacy and safety of selective FXa inhibitors
(such as fondaparinux, rivaroxaban, apixaban) and direct thrombin inhibitors (such as lepirudin,
bivalirudin, dabigatran etexilate) in the treatment of typical indications for conventional vitamin K
antagonists, in particular, the prevention and treatment of venous thromboembolism. This review
summarizes the results and designs of recently published and ongoing clinical trials of novel
anticoagulants.
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ABSTRACT 
 
Vitamin-K antagonists are the mainstay in the prevention and treatment of 
thromboembolic diseases. Although effective under optimal conditions, several 
drawbacks are imminent to the long-term application of these drugs due to their narrow 
therapeutic window, interactions with other drugs as well as the need for regular 
monitoring and the risk of a recurrent event versus the risk of bleeding. To overcome 
these downsides, novel anticoagulants are being developed; in contrast to vitamin K 
antagonists, these novel agents specifically and selectively block central elements of 
the coagulation cascade. Several clinical trials have demonstrated the efficacy and 
safety of selective FXa inhibitors (such as fondaparinux, rivaroxaban, apixaban) and 
direct thrombin inhibitors (such as lepirudin, bivalirudin, dabigatran etexilate) in the 
treatment of typical indications of conventional vitamin K antagonists, in particular the 
prevention and treatment of venous thromboembolism. This review summarizes the 
results and designs of recently published and ongoing clinical trials of novel 
anticoagulants.  
 
Word count: 152 words 
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Condensed Abstract 
Several novel anticoagulants that selectively target specific stages of the coagulation 
cascade are being developed and investigated in clinical trials. This review discusses 
completed and ongoing clinical studies of these agents, focusing on Factor Xa inhibitors 
(such as fondaparinux, rivaroxaban, apixaban) and direct thrombin inhibitors (including, 
bivalirudin, dabigatran etexilate). 
 
Word count: 48 words (maximum approx 50) 
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INTRODUCTION 
 
 Activation of the coagulation cascade is the central mechanism of arterial and 
venous thrombus formation. Contact of tissue factor (TF) with circulating factor (F) VIIa 
results in the formation of the TF-VIIa complex leading to the conversion of FIX to IXa 
and X to Xa. In complex with factor Va, phospholipids and calcium, FXa catalyses the 
conversion of prothrombin (FII) to thrombin (FIIa), leading to fibrin formation, platelet 
activation and, ultimately, generation of a  thrombus.[1] In addition (and important for 
sustained activation of coagulation), initiation of the intrinsic coagulation cascade occurs 
by means of an auto-feedback loop, in which thrombin, via activation of FXIa, FVIIIa, 
and FIXa, initiates the conversion of large amounts of FX to FXa (Fig. 1). 
Vitamin K antagonists are the preferred treatment for long-term anticoagulation in 
the therapy and prophylaxis of thromboembolic diseases, stroke prevention in atrial 
fibrillation, and after implantation of mechanical heart valves.[2] The preferentially used 
agents differ primarily in their half lives, which ranges from 9 hours (Acenocoumarol, 
Sintrom®) over 30-40 hours (Warfarin, Coumadin®) up to 120-160 hours 
(Phenprocoumon, Marcoumar®).[3] Although therapy with vitamin K antagonists is 
usually effective under optimal conditions, long-term application may be problematic 
due to the narrow therapeutic window of these agents,[2, 4] necessitating life-long 
monitoring of coagulation intensity (initially 2-3 times weekly, later at least once 
monthly). Due to their high degree of protein binding, other drugs may compete with 
vitamin K antagonists for that, markedly altering their anticoagulant effects. As such, the 
risk of a recurrent event (in the case of insufficient anticoagulation) as well as the risk of 
bleeding and especially of intracranial bleeding (in the case of excessive 
anticoagulation) are always possible.  
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For acute events, unfractionated heparin (UFH) or low-molecular weight heparin 
(LMWH) is typically employed for initial anticoagulation, the latter usually being 
preferred due to the ease of application (once daily subcutaneous injection as 
compared to permanent intravenous infusion) and the lack of need for monitoring (in the 
absence of renal insufficiency). Hence, LMWH have some advantages also over oral 
anticoagulation with vitamin K antagonists; their long-term application, however, is 
complicated mainly because of the route of administration. 
As a result, several novel substance are being developed for the prevention and 
treatment of venous thromboembolic disorders as well as for stroke prevention in atrial 
fibrillation as a potential substitute for vitamin K antagonists. This review summarizes 
currently ongoing and recently published clinical trials of the most popular and most 
promising agents, as well as their current indications as approved by the European 
Medicines Agency (EMEA; Tab. 1), updating previous publications of the authors. 
 
 
NOVEL ANTICOAGULANTS 
   
In contrast to vitamin K antagonists, which inhibit the coagulation cascade by 
preventing -carboxylation of vitamin-K dependent coagulation factors II, VII, IX and X, 
the novel substances discussed here selectively inhibit central coagulation proteins (Fig. 
1). 
 
Factor Xa inhibitors 
FXa inhibitors are divided into “indirect” inhibitors (e.g., fondaparinux, idraparinux, 
idrabiotaparinux),  which prevent FXa activity via its „physiologic“ inhibitor antithrombin, 
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and “direct” inhibitors (e.g., rivaroxaban, apixaban), which directly block FXa through 
binding to its catalytic subunit independently of antithrombin (Fig. 1). In both cases, 
inhibition of FXa leads to diminished conversion of prothrombin to thrombin resulting in 
reduced thrombus formation. 
 
Fondaparinux 
The pentasacharide fondaparinux differs from LMWH by its much higher affinity 
to antithrombin (and hence indirectly to FXa). After subcutaneous injection it is 
absorbed quickly and in a predictable manner, rendering drug-monitoring unnecessary; 
it is, however, eliminated almost exclusively by the kidneys, making it unsuitable for 
patients with renal failure.[5]  
The efficacy of fondaparinux in the prevention and treatment of venous 
thromboembolic disorders in orthopedic patients was mainly studied in 4 clinical trials 
(EPHESUS, PENTATHLON, PENTAMAKS, PENTHIFRA). In a meta-analysis of these 
studies, fondaparinux reduced thromboembolic events by more than 50% as compared 
to enoxaparin; while an increase in bleeding was observed, “clinically relevant” bleeding 
complications did not differ between the two treatments.[6] In the ARTEMIS trial, 
fondaparinux was also shown to be effective for thromboembolic prophylaxis in medical 
patients (at similar rates of severe bleeding).[7] The efficacy and safety of fondaparinux 
in the initial treatment of pulmonary embolism[8] and deep venous thrombosis (DVT)[9] 
was shown in the MATISSE study; a pilot study also demonstrated good results in the 
long-term treatment for this indication.[10]  
In the OASIS-5 trial, fondaparinux was compared to enoxaparin in 20'078 
patients with acute coronary syndrome (ACS). No difference was found in the combined 
primary endpoint (death, myocardial infarction, or refractory angina) after 9 days, while 
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severe bleeding was less frequent under fondaparinux (2.2% vs. 4.1%). In the analysis 
of secondary endpoints, death was significantly less likely to occur with fondaparinux 
after 30 days (295 vs. 352) as well as after 180 days (574 vs. 638).[11] In 12'092 
patients with ST-elevation myocardial infarction (STEMI), studied in the OASIS-6 trial, 
fondaparinux was compared to UFH or to placebo (if UFH was considered not 
indicated).[12] Death or re-infarction was significantly reduced in the fondaparinux group 
(9.7% vs. 11.2%) at similar rates of bleeding; moreover, and similar to OASIS-5, 
mortality was reduced with fondaparinux.[12] The benefit of fondaparinux was most 
pronounced in patients in which either thrombolysis or no reperfusion was performed; in 
contrast, no difference was observed as compared to standard therapy in patients 
treated with primary percutaneous coronary intervention (PCI)[12] due to the frequent 
occurrence of guiding catheter thromboses during intervention under fondaparinux.  
 Fondaparinux (Arixtra®) is currently approved by the EMEA for prevention of 
venous thromboembolic events in patients undergoing major orthopedic surgery of the 
lower limbs, in patients undergoing abdominal surgery considered to be at high risk of 
thromboembolic complications, and in medical patients judged to be at high risk of 
thromboembolic complications; it may furthermore be used for the treatment of acute 
DVT and pulmonary embolism  in uncomplicated, stable patients. Fondaparinux is also 
approved for the treatment of unstable angina or non-ST segment elevation myocardial 
infarction (NSTEMI) as well as in patients with ST segment elevation myocardial 
infarction (STEMI) who are undergoing thrombolysis or who initially do not receive no 
other reperfusion therapy. 
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Idraparinux 
Idraparinux is a synthetic pentasacharide with a strong affinity to antithrombin, 
resulting in a half-life of approximately 80 hours requiring only once weekly 
subcutaneous administration.[13] Due to its predictable bioavailability, drug-monitoring 
was deemed unnecessary. The drug is excreted by the kidneys, which is why it is 
contraindicated in renal insufficiency (creatinine clearance < 30ml/min).[14] The efficacy 
and safety of idraparinux as compared to UFH plus oral anticoagulation for the 
treatment of DVT and pulmonary embolism  was studied in the phase III VAN GOGH 
trial.[15] After 3 months, treatment with idraparinux was non-inferior to standard therapy, 
resulting in similar rates of recurrent thrombosis (2.9% vs. 3.0%) but significantly less 
bleeding (4.5% vs. 7.0%); after 6 months, the rate of bleeding was similar in both 
groups. In patients with pulmonary embolism, however, a recurrent event occurred 
significantly more frequently with idraparinux as compared to UFH and oral 
anticoagulation (4.5% vs. 7.0%), which lead to its failure to reach the pre-specified non-
inferiority margin.[15] In the follow-up study of 1215 patients in which a prolonged 
anticoagulation was indicated, a recurrent thromboembolic event was observed in 1.0% 
under idraparinux vs. 3.7% under oral anticoagulation (p=0.002); severe bleeding 
complications, however, were more frequent under idraparinux (11 episodes, including 
3 fatal intracranial bleeds, as compared to none under oral anticoagulation).[16]  
A similar situation was found in patients with atrial fibrillation; the AMADEUS 
study, in which 4576 patients were randomized to receive either idraparinux or oral 
anticoagulation, had to be stopped early because of an increased bleeding rate under 
idraparinux (19.7 vs. 11.3 per 100 patient-years).[17] The development of idraparinux 
was subsequently terminated as a result of the apparently increased bleeding risk, 
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which most likely occurred due to the long half-life of the drug combined with the lack of 
an antidote. 
 
Idrabiotaparinux (SSR 126517) 
Idrabiotaparinux, the biotinylated equivalent of idraparinux, is very similar to its 
predecessor from a pharmacokinetic point of view; in contrast, however, the introduction 
of the biotin moiety allows for rapid antagonisation of its action with avidin. Phase III 
clinical trials investigating the safety and efficacy of idrabiotaparinux as compared to 
standard OAC in the treatment of patients with thromboembolic diseases 
(CASSIOPEA)[18] and atrial fibrillation (BOREALIS-AF)[19] are currently underway. 
 
Rivaroxaban 
Rivaroxaban is an oral FXa inhibitor, which inhibits FXa both in its free as well as 
in its prothrombin-bound state. Its half life is 6-9 hours requiring once to twice daily 
dosing.[20] It has a dual mode of elimination, with approximately one-third of the drug 
being eliminated unchanged by the kidneys, and two-thirds being metabolized by the 
liver, and is contraindicated in patients with severe hepatic insufficiency or severe renal 
failure.  
The REgulation of Coagulation in major Orthopaedic surgery reducing the Risk of 
Deep vein thrombosis and pulmonary embolism (RECORD) phase III programme 
consisted of four randomized, double-blind studies in >12 500 patients, and showed that 
rivaroxaban regimens were superior to enoxaparin regimens for the prevention of 
venous thromboembolism (VTE) after total knee or hip replacement surgery. [21-24] 
The efficacy of rivaroxaban in the treatment of DVT was demonstrated in 2 phase 
IIb studies (ODXa-DVT, EINSTEIN-DVT) in over 1150 patients.[25, 26] Both studies 
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suggested that rivaroxaban had similar efficacy to standard anticoagulation therapy for 
the treatment of proximal DVT; recurrence rate of VTE was also low. Phase III trials for 
the treatment as well as for the long-term prevention of DVT are underway.[27] 
In the ongoing phase III ROCKET-AF study, rivaroxaban is being evaluated 
against standard therapy for stroke prevention in over 14’000 patients with atrial 
fibrillation.[28]  
The phase II randomized, double-blind, placebo-controlled, dose-finding ATLAS 
ACS TIMI 46 study investigated rivaroxaban for the secondary prevention of fatal and 
non-fatal cardiovascular events in patients with recent ACS who were receiving 
standard antiplatelet therapy of low-dose acetylsalicylic acid (ASA) or ASA and 
thienopyridine. Preliminary results (presented at the AHA meeting 2008) showed that 
rivaroxaban therapy dose-dependently increased the risk of bleeding; also, a (non-
significant) RRR compared with placebo was observed  (21%; hazard ratio [HR] 0.79; 
p=0.1) for the primary endpoint of death, MI, stroke or severe recurrent ischemia 
requiring revascularization (although the trial was not powered to investigate efficacy 
endpoints).[29] Based on these phase II results, the most promising doses of 
rivaroxaban (2.5mg bid and 5mg bid) were chosen for the phase III ATLAS TIMI 51 trial, 
which is currently underway. 
 Rivaroxaban (Xarelto®) is approved in the European Union and several other 
countries worldwide for the prevention of venous thromboembolism in patients 
undergoing elective hip or knee replacement surgery. 
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Apixaban 
Similar to rivaroxaban, the oral direct FXa inhibitor apixaban binds both free as 
well as prothrombin-bound FXa. Its elimination route via the fecal route of about 70% 
may prove advantageous in patients with renal impairment.  
The use of apixaban in the prevention of venous thromboembolic events was 
compared to enoxaparin or open-label warfarin in the phase II APROPOS trial in 1238 
patients undergoing elective knee replacement surgery. While no difference in the 
primary endpoint (thromboembolic event, death) was detected amongst the three 
treatment strategies, a significantly increased bleeding risk was observed in the 
apixaban group as compared to enoxaparin or oral anticoagulation.[30] In the first 
phase III study for the same indication (ADVANCE-1), the primary endpoint was 
reached to a similar extent in patients under apixaban as compared to enoxaparin 
(9.0% vs. 8.9%); due to the low absolute event rate, however, these results were 
insufficient to reach statistical non-inferiority.[31, 32] Further phase III studies for 
thromboembolic prophylaxis as well as for the treatment of DVT and pulmonary 
embolism  are underway.[33, 34]  
In the phase II APPRAISE-1 trial, which was recently presented at the 2008 
European Society of Cardiology meeting, treatment with apixaban plus aspirin (+/- 
clopidogrel) was associated with a trend towards a reduction in clinical ischemic events 
at the cost of a dose-dependent increase in bleeding complications when used in 
patients with recent ACS; a phase III trial for this indication is underway (APPRAISE-2).  
The efficacy and safety of apixaban for stroke prevention in atrial fibrillation is 
currently being investigated in two phase III studies: In the AVERROES trial 
(approximately 5600 patients), patients not eligible for oral anticoagulation are treated 
with either apixaban or aspirin,[35] while in the much larger ARISTOTLE trial, which is 
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planned to include approximately 16’000 patients, apixaban is directly compared to 
treatment with vitamin K antagonists.[36]  
For a series of other oral FXa inhibitors in rather early stages of development, 
phase II studies are currently ongoing or have recently been completed (e.g., 
YM150[37-40], Otamixaban,[41, 42] PRT-054021 (Betrixaban),[43, 44] DU-176b[45, 
46], and others). 
 
 
Direct Thrombin Inhibitors 
 
Direct thrombin inhibitors selectively block the activity of thrombin (both in 
solution as well as in its fibrin-bound state), thus preventing the conversion of fibrinogen 
to fibrin and in turn thrombus formation (Fig. 1). 
The parenteral direct thrombin inhibitor lepirudin (a recombinant hirudin 
derivative) is routinely used to treat heparin induced thrombocytopenia. The first oral 
direct thrombin inhibitor ximelagatran was already far advanced in its clinical 
development (with positive results both in DVT prophylaxis as well as stroke prevention 
in atrial fibrillation) when it had to be withdraw from the market in February of 2006 
because of hepatotoxic side effects.[47] Several other parenteral and oral direct 
thrombin inhibitors are nonetheless being developed or are already in clinical use (e.g. 
bivalirudin). 
 
Bivalirudin 
The hirudin-derivative bivalirudin is administered intravenously and has a half-life 
of approximately 25 minutes.[48]  
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Already over 10 years ago, the bivalirudin angioplasty study showed a better 
efficacy as well as lower bleeding rates under bivalirudin as compared to UFH in 4098 
patients undergoing percutaneous transluminal coronary angioplasty (PTCA) for 
unstable- or post-infarct angina.[49] In the REPLACE-2 study (published 8 years later), 
bivalirudin (with or without GpIIb/IIIa inhibitor) was compared to heparin plus GpIIb/IIIa 
inhibitor in patients with planned or urgent PCI; the combined primary endpoint 
(mortality, myocardial infarction, urgent revascularization, or severe bleeding) was 
reached in 9.2% and 10%, respectively (p=0.32%) demonstrating non-inferiority of 
bivalirudin (at significantly less bleeding, 2.4% vs. 4.1%).[50] Similarly, no difference in 
the primary quadruple endpoint (death, myocardial infarction, urgent revascularization 
and severe bleeding) was found between bivalirudin and heparin in the recently 
published ISAR-REACT 3 trial in troponin-negative patients undergoing PCI; the 
reduced bleeding risk under bivalirudin was counterbalanced by the tendentially 
increased secondary triple end point (death, myocardial infarction, or urgent 
revascularization), which occurred in 5.9% and 5.0% under bivalirudin and UFH, 
respectively.[51] In the ACUITY study, 13'819 patients with unstable angina or NSTEMI 
were treated with either bivalirudin, bivalirudin plus GpIIb/IIIa inhibitor, or standard 
therapy (GpIIb/IIIa antagonist plus either UFH or enoxaparin). The primary ischemic 
endpoint (death, MI, unplanned revascularization because of ischemia) as well as the 
overall outcome (ischemic endpoint and bleeding) was similar between the standard 
group and those treated with bivalirudin plus GpIIb/IIIa. However, patients treated with 
bivalirudin only had a significantly reduced risk for bleeding (3.0% vs. 5.7%) as 
compared to the standard treatment group (at similar ischemic event rates), which 
translated into an improved outcome (reduction in overall outcome endpoint from 11.7% 
to 10.1%).[52] Finally, in 3602 patients with STEMI (HORIZONS-AMI trial), bivalirudin 
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reduced bleeding complications from 8.3% to 4.9% as compared to UFH, leading to an 
improved 30-day mortality rate (3.1% vs. 2.1%).[53] Although oftentimes criticized 
(especially because of the high “non-inferiority” margin of 25% in the ACUITY study), 
these trials collectively imply that in ACS patients bivalirudin has a similar efficacy as 
compared to UFH at a lower risk for bleeding. However, bivalirudin’s final place in the 
armamentarium of anticoagulants remains to be determined, last but not least because 
of its high cost (as compared to UFH), which was extensively discussed recently in the 
context of the ISAR-REACT 3 trial.[51] 
Phase III studies evaluating the use of bivalirudin in patients with heparin-induced 
throbocytopenia undergoing PCI[54] or aorto-coronary bypass grafting[55] are currently 
ongoing. Large studies examining bivalirudin for prophylaxis of thromboembolic events 
(DVT, PE, atrial fibrillation) have not been conducted; given its short half-life, the need 
for continuous i.v. application, and the need for frequent monitoring, it is not suitable for 
this indication.  
Currently, bivalirudin (Angiox®) is EMEA approved for the treatment of unstable 
angina or NSTEMI planned for urgent or early intervention (plus aspirin and 
clopidogrel), and as an anticoagulant in patients undergoing PCI.  
 
Dabigatran etexilate 
The oral direct thrombin inhibitor dabigatran etexilate is absorbed as a prodrug 
and subsequently converted into its active form. Elimination is 80% renal, and the drug 
is contraindicated in patients with renal failure. 
In the phase III RE-NOVATE study in 3493 patients undergoing elective hip 
replacement, dabigatran etexilate was compared to enoxaparin as thromboembolic 
prophylaxis. The primary endpoint was reached in 6.7% of patients on enoxaparin as 
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compared to 6.0% and 8.6% in those taking 200mg and 150mg dabigatran etexilate, 
respectively, demonstrating non-inferiority of dabigatran etexilate compared to standard 
treatment.[56] In a similar phase III study of patients undergoing elective hip 
replacement (RE-MODEL), the primary endpoint (thromboembolic event or death) was 
reached in 37.7%, 36.4%. and 40.5% in patients under enoxaparin, dabigatran etexilate 
220mg, and dabigatran etexilate 150mg, respectively, again meeting non-inferiority of 
both doses of dabigatran etexilate as compared to standard therapy.[57] Severe 
bleeding or an increase in liver enzymes was observed to the same extent in all 3 
groups. Two phase III trials (RE-COVER and RE-MEDY) investigating the use of 
dabigatran etexilate for secondary prevention of venous thromboembolic events are 
underway.[58, 59] 
In the phase II PETRO study, 502 patients with atrial fibrillation were treated with 
dabigatran etexilate (50mg, 150mg, or 300mg twice daily) alone or in combination with 
aspirin or warfarin for stroke prevention.[60] Treatment with 2x150mg dabigatran 
etexilate showed a similar efficacy and safety as compared to standard oral 
anticoagulants, leading to the initiation of a phase III trial (RE-LY) comparing dabigatran 
etexilate (150mg or 110mg) with vitamin K antagonists for this indication.[61] Results of 
this first major phase III study for thromboembolic prevention in atrial fibrillation are 
expected in September 2009. A placebo-controlled phase II study (RE-DEEM) 
comparing dabigatran etexilate (plus aspirin and clopidogrel) for secondary prophylaxis 
after myocardial infarction is also underway.[62] 
 At present, dabigatran etexilate (Pradaxa®) is approved by the EMEA for the 
prevention of venous thromboembolic events in patients undergoing elective total hip or 
knee replacement surgery. 
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CONCLUSIONS 
 
 Several novel anticoagulants have been developed in the quest for an alternative 
to the clinically difficult to use vitamin K antagonists. Selective FXa inhibitors as well as 
direct thrombin inhibitors have been most extensively studied in this regard; while most 
of these substances are currently still undergoing clinical studies, some have already 
been approved and are used in routine clinical practice (e.g., fondaparinux, bivalirudin). 
Ideally, these next-generation anticoagulants should possess a number of properties 
(Fig. 2), including an enhanced safety and efficacy profile, oral bioavailability, and no 
requirement for routine coagulation monitoring, all of which would be particularly 
convenient in the long-term prevention of venous thromboembolic events or stroke in 
atrial fibrillation. In spite of mostly positive results in recent trials, the experience with 
ximelagatran has shown that only long-term application in large numbers of patients will 
show how these novel agents compare with established oral anticoagulation with 
vitamin K antagonists in terms of efficacy, safety and adverse drug reactions. Amongst 
the safety issues, bleeding complications belong to the most dreaded side effects of 
anticoagulants; indeed, none of the novel anticoagulants (except for Idrabiotaparinux) 
has an antidote, which may complicate treatment especially in patients at an increased 
risk for bleeding. In such patients, monitoring of the intensity of anticoagulation would be 
desirable; however, at present it is unclear in most cases, which value (aPTT, anti-FXa 
activity, INR, drug level) is suitable and appropriate for monitoring which substance, and 
in which range the target values are to be expected. Furthermore, future trials will have 
to show whether these novel anticoagulants are also safe and effective in particularly 
challenging situations such as thromboembolic prophylaxis in pregnancy or in tumor 
patients. 
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In view of the mostly positive trial results, it seems likely that one day vitamin K 
antagonists will be replaced by one (or potentially several) novel drugs for their current 
indications. This, however, will only take place once long-term large-scale studies have 
demonstrated a better efficacy and safety for these novel agents as compared to 
standard oral anticoagulation. 
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LEGENDS TO FIGURES AND TABLE 
 
Figure 1: Coagulation cascade and effect of novel anticoagulants  
See text for details. p.o. = per os; s.c. = subcutaneous;  i.v. = intravenous. 
Reproduced with permission from:  Steffel J, Lüscher TF. Neue Antikoagulantien – 
«Confused at a higher level»? Kardiovaskuläre Medizin. 2008;11(12):337–45. EMH 
Swiss Medical Publishers Ltd., Muttenz, Switzerland, Copyright © 2008. 
 
Figure 2: Novel anticoagulants – “ideal” properties and current limitations 
Modified from:  Steffel J, Lüscher TF. Neue Antikoagulantien – «Confused at a higher 
level»? Kardiovaskuläre Medizin. 2008;11(12):337–45. EMH Swiss Medical Publishers 
Ltd., Muttenz, Switzerland, Copyright © 2008. 
 
Table 1: Overview over the most important studies involving the substances 
discussed in the text. 
Modified from:  Steffel J, Lüscher TF. Neue Antikoagulantien – «Confused at a higher 
level»? Kardiovaskuläre Medizin. 2008;11(12):337–45. EMH Swiss Medical Publishers 
Ltd., Muttenz, Switzerland, Copyright © 2008. 
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Table 1:  
Substance Studied Indications EMEA appr. 
  DVT prevention DVT / PE treatment Atrial fibrillation ACS  
       
Fondaparinux  --- 
(GlaxoSmith 
Kline)  
Phase III (EPHESUS, 
PENTHATLON, PENTAMAKS, 
ARTEMIS etc.), published[6, 7] 
Phase III (MATISSE), 
published[8, 9] Pilot (long-
term), published[10] 
 
Phase III (OASIS-5, 
OASIS-6 etc.), 
published[11, 12] 
VTE prevention 
(orthopedic / abdominal 
surgery and medical 
patients); ACS not 
undergoing PCI 
        
Idraparinux  --- --- 
(Sanofi‐Aventis)   
Phase III (VAN GOGH, 
extension), published[15, 16]
Phase III (AMADEUS), 
published (terminated early)[17] 
  
Development terminated 
due to increased 
bleeding 
        
SSR126517E  ---  
(Sanofi‐
Phase III (EQUINOX), 
completed[63] 
Phase III (CASSIOPEA), 
ongoing[18] 
Phase III (BOREALIS-AF), 
ongoing[19] 
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Aventis)  
            
Rivaroxaban 
(Bayer) 
Phase III (RECORD 1-4), 
published[21-24] 
Phase II (ODIXa-DVT, 
EINSTEIN-DVT, 
published[25, 26]  
Phase III , ongoing[27] 
Phase III (ROCKET-AF), 
ongoing[28] 
Phase II (ATLAS ACS 
TIMI 46), presented[29]
Phase III (ATLAS ACS 
TIMI 51), ongoing 
VTE prevention in adults 
after hip or knee 
replacement surgery 
        
Apixaban  Phase III, ongoing[64]  
(Pfizer / BMS) 
Phase II (APROPOS), 
published;[30] Phase III, 
completed (ADVANCE-1)[31] / 
ongoing[34] 
 
Phase III (AVERROES, 
ARISTOTLE), ongoing[35, 36] 
Phase III (APPRAISE-
1), presented[65] 
APPRAISE-2, ongoing 
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 Bivalirudin  --- --- --- 
(Nycomed)      
During PCI (Phase III; 
REPLACE-2, ISAR-
REACT 3 etc.), 
published[48, 50, 51] 
Unstable angina / 
NSTEMI planned for PCI; 
anticoagulant during PCI 
       
     
ACS (Phase III; 
ACUITY, HORIZONS-
AMI etc.),                   
published[52, 53]  
        
Dabigatran 
etexilate 
Phase III RE-MEDY, RE-
COVER), ongoing[58, 59] 
(Boehringer) 
Phase III (RE-NOVATE, RE-
MODEL, RE-MOBILIZE), 
published[56, 57] 
 
Phase II (PETRO), published[60] 
Phase III (RE-LY), ongoing[61] 
Phase II (Secondary 
prevention, RE-DEEM), 
ongoing[62] 
VTE prevention after total 
hip or knee replacement 
surgery 
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Figure 1: 
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 Novel Anticoagulants 
Open questions  
  
  Application in special situations  
 (e.g., pregnancy, malignancy) ? 
 Monitoring? Which value for  
 which agent? Target values? 
  Cost effectiveness? 
  Data from Phase IV studies  
 pending 
The „ideal“ agent 
 
  Good efficacy 
  Low bleeding risk 
  Fixed dose 
  Applicable in renal  
insufficiency 
  No monitoring necessary 
  Oral bioavailability 
  Antidote available 
  Data from large-scale  
long-term trials available 
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Figure 2: 
